Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut

By Yahoo! Finance | 3 weeks ago

Moderna's mRNA-1018 avian influenza vaccine shows strong immune response in trial. Despite positive results, U.S. HHS cancels funding, creating uncertainty. Moderna plans to explore other options for vaccine development. Future study data will be shared at a scientific conference.

Did you find this insightful?